In the past few months, troubling reports have surfaced regarding Xarelto, an anticoagulant, and the risk of internal bleeding. Xarelto is a commonly used blood thinner that is used to prevent blood cluts, pulmonary embolism and deep vein thrombosis. Xarelto came on the market in 2011 from Janssen Pharmaceuticals. It was touted as an alternative to Coumadin, which has been the most popular blood thinner in recent years.
This litigation comes on the heels of the announcement of Pradaxa settlements. Much like Xarelto, Pradaxa was a blood thinner that caused internal bleeding. In May, Boehringer Ingelheim agreed to pay $650 million in settlements to thousands of claimants.
On October 15, 2014, a motion to consolidate or form an “MDL” for the Xarelto litigation was filed before U.S. District Judge David R. Herndon in the Southern District of Illinois.
Despite the litigation, Xarelto sales continue to increase. It is expected that by 2018, Xarleto will generate about $3.68 billion in annual sales.
Hiring a lawyer is the first step on your path towards achieving a better quality of life. At Pierce Skrabanek, we devote our undivided attention to each client, and all communications are held in the strictest privacy. We are ready to guide you through the process and support you at every step of the way. Contact us by filling out the form or calling us directly at (832) 690-7000.
3701 Kirby Drive
Houston, TX, 77098
Phone: (832) 690-7000
Fax: (832) 616-5576
The attorney responsible for the content of this web site is Michael Pierce.
Disclaimer | Terms & Conditions